Logo image of GYRE

GYRE THERAPEUTICS INC (GYRE) Stock Fundamental Analysis

USA - NASDAQ:GYRE - US4037831033 - Common Stock

7.29 USD
-0.08 (-1.09%)
Last: 9/25/2025, 4:30:01 PM
7.29 USD
0 (0%)
After Hours: 9/25/2025, 4:30:01 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to GYRE. GYRE was compared to 538 industry peers in the Biotechnology industry. GYRE has an excellent financial health rating, but there are some minor concerns on its profitability. GYRE is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year GYRE was profitable.
GYRE had a positive operating cash flow in the past year.
GYRE had negative earnings in 4 of the past 5 years.
GYRE had negative operating cash flow in 4 of the past 5 years.
GYRE Yearly Net Income VS EBIT VS OCF VS FCFGYRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M

1.2 Ratios

GYRE has a Return On Assets of 2.73%. This is amongst the best in the industry. GYRE outperforms 91.08% of its industry peers.
GYRE's Return On Equity of 4.53% is amongst the best of the industry. GYRE outperforms 92.01% of its industry peers.
GYRE has a Return On Invested Capital of 5.30%. This is amongst the best in the industry. GYRE outperforms 92.57% of its industry peers.
Industry RankSector Rank
ROA 2.73%
ROE 4.53%
ROIC 5.3%
ROA(3y)-33.04%
ROA(5y)-63.26%
ROE(3y)-80.93%
ROE(5y)-106.13%
ROIC(3y)N/A
ROIC(5y)N/A
GYRE Yearly ROA, ROE, ROICGYRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

With an excellent Profit Margin value of 4.08%, GYRE belongs to the best of the industry, outperforming 91.08% of the companies in the same industry.
GYRE has a better Operating Margin (9.14%) than 91.82% of its industry peers.
GYRE has a better Gross Margin (95.91%) than 94.61% of its industry peers.
Industry RankSector Rank
OM 9.14%
PM (TTM) 4.08%
GM 95.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GYRE Yearly Profit, Operating, Gross MarginsGYRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), GYRE is destroying value.
Compared to 1 year ago, GYRE has more shares outstanding
GYRE has more shares outstanding than it did 5 years ago.
There is no outstanding debt for GYRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GYRE Yearly Shares OutstandingGYRE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
GYRE Yearly Total Debt VS Total AssetsGYRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

GYRE has an Altman-Z score of 7.47. This indicates that GYRE is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 7.47, GYRE belongs to the best of the industry, outperforming 81.41% of the companies in the same industry.
GYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.47
ROIC/WACC0.54
WACC9.87%
GYRE Yearly LT Debt VS Equity VS FCFGYRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 5.40 indicates that GYRE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.40, GYRE is in line with its industry, outperforming 59.48% of the companies in the same industry.
A Quick Ratio of 4.87 indicates that GYRE has no problem at all paying its short term obligations.
GYRE has a Quick ratio of 4.87. This is comparable to the rest of the industry: GYRE outperforms 54.83% of its industry peers.
Industry RankSector Rank
Current Ratio 5.4
Quick Ratio 4.87
GYRE Yearly Current Assets VS Current LiabilitesGYRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 104.97% over the past year.
The Revenue for GYRE has decreased by -38.38% in the past year. This is quite bad
Measured over the past years, GYRE shows a very strong growth in Revenue. The Revenue has been growing by 143.34% on average per year.
EPS 1Y (TTM)104.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-87.28%
Revenue 1Y (TTM)-38.38%
Revenue growth 3Y143.34%
Revenue growth 5YN/A
Sales Q2Q%6.13%

3.2 Future

The Earnings Per Share is expected to grow by 77.26% on average over the next years. This is a very strong growth
GYRE is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y-61.14%
EPS Next 2Y94.64%
EPS Next 3Y77.26%
EPS Next 5YN/A
Revenue Next Year1.96%
Revenue Next 2Y22.95%
Revenue Next 3Y26.38%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GYRE Yearly Revenue VS EstimatesGYRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M
GYRE Yearly EPS VS EstimatesGYRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -500 -1K

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

GYRE is valuated quite expensively with a Price/Earnings ratio of 182.25.
GYRE's Price/Earnings ratio is rather cheap when compared to the industry. GYRE is cheaper than 90.15% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.29, GYRE is valued quite expensively.
With a Price/Forward Earnings ratio of 6.11, the valuation of GYRE can be described as very cheap.
Based on the Price/Forward Earnings ratio, GYRE is valued cheaper than 98.14% of the companies in the same industry.
GYRE's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.80.
Industry RankSector Rank
PE 182.25
Fwd PE 6.11
GYRE Price Earnings VS Forward Price EarningsGYRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, GYRE is valued cheaper than 90.33% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 52.28
GYRE Per share dataGYRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

GYRE's earnings are expected to grow with 77.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y94.64%
EPS Next 3Y77.26%

More info and screens

0

5. Dividend

5.1 Amount

GYRE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GYRE THERAPEUTICS INC

NASDAQ:GYRE (9/25/2025, 4:30:01 PM)

After market: 7.29 0 (0%)

7.29

-0.08 (-1.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-11 2025-11-11
Inst Owners3.02%
Inst Owner Change30.59%
Ins Owners7.25%
Ins Owner Change2.09%
Market Cap662.15M
Analysts82.5
Price Target19.38 (165.84%)
Short Float %14.92%
Short Ratio19.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.3%
Min EPS beat(2)-34.64%
Max EPS beat(2)-1.96%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-19.32%
Min Revenue beat(2)-23.85%
Max Revenue beat(2)-14.79%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5%
PT rev (3m)-5%
EPS NQ rev (1m)66.67%
EPS NQ rev (3m)66.67%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-0.74%
Revenue NQ rev (3m)2.55%
Revenue NY rev (1m)-2.19%
Revenue NY rev (3m)-2.19%
Valuation
Industry RankSector Rank
PE 182.25
Fwd PE 6.11
P/S 6.48
P/FCF N/A
P/OCF 714.29
P/B 7.2
P/tB 7.61
EV/EBITDA 52.28
EPS(TTM)0.04
EY0.55%
EPS(NY)1.19
Fwd EY16.37%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.01
OCFY0.14%
SpS1.13
BVpS1.01
TBVpS0.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.73%
ROE 4.53%
ROCE 6.88%
ROIC 5.3%
ROICexc 8.85%
ROICexgc 9.42%
OM 9.14%
PM (TTM) 4.08%
GM 95.91%
FCFM N/A
ROA(3y)-33.04%
ROA(5y)-63.26%
ROE(3y)-80.93%
ROE(5y)-106.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 122.05%
Cap/Sales 2.49%
Interest Coverage 250
Cash Conversion 8.12%
Profit Quality N/A
Current Ratio 5.4
Quick Ratio 4.87
Altman-Z 7.47
F-Score5
WACC9.87%
ROIC/WACC0.54
Cap/Depr(3y)333.79%
Cap/Depr(5y)313.61%
Cap/Sales(3y)3.51%
Cap/Sales(5y)4.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)104.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-87.28%
EPS Next Y-61.14%
EPS Next 2Y94.64%
EPS Next 3Y77.26%
EPS Next 5YN/A
Revenue 1Y (TTM)-38.38%
Revenue growth 3Y143.34%
Revenue growth 5YN/A
Sales Q2Q%6.13%
Revenue Next Year1.96%
Revenue Next 2Y22.95%
Revenue Next 3Y26.38%
Revenue Next 5Y-14.87%
EBIT growth 1Y-75.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y90.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y105.3%
OCF growth 3YN/A
OCF growth 5YN/A